Drug intelligence / Profile preview

SLI-F06

Development stage: Phase 2
Lead developer: Scarless Laboratories
Modality: Peptides, Small Molecules
Administration: Intradermal

Overview

SLI-F06 is a synthetic, fibromodulin-based peptide developed to enhance wound healing and reduce cutaneous scarring. It acts as an anti-fibrotic agent by modulating collagen, promoting fibroblast migration, contraction, and collagen cross-linking. These actions accelerate the reestablishment of wound tensile strength while reducing fibrosis. Preclinical studies in animal models (mice, rats, pigs) have demonstrated its pro-migration, pro-tensile strength, and anti-fibrotic properties. Clinical trials have focused on improving scar appearance and wound healing following surgical excisions such as abdominoplasty. The drug is being developed primarily for the reduction of hypertrophic scars and improvement of post-surgical wound healing[1][2][3][4][5][6][7].

Other names: Fibromodulin derived peptide

Beyond the preview

Go deeper on SLI-F06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLI-F06.

Explore the full profile